Genetics has transformed neurodegeneration research by identifying both high-penetrance causal variants and common risk alleles that modify susceptibility. Mendelian discoveries
first defined core disease mechanisms in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, and [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--[1][2]. Large [genome-wide association
studies[/technologies/[gwas[/technologies/[gwas[/technologies/[gwas[/technologies/[gwas--TEMP--/technologies)--FIX-- then expanded these architectures by showing polygenic risk and shared pathways in [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--, [endolysosomal dysfunction], and
[proteostasis][3][4].
A practical framework separates:
This distinction matters for therapeutic strategy. Causal-mutation disorders are often approached with mutation-targeted therapies, while risk-allele biology supports pathway-level intervention and prevention approaches[5][6].
Autosomal dominant familial [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- is classically driven by pathogenic variants in [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--, [PSEN1[/genes/[psen1[/genes/[psen1[/genes/[psen1[/genes/[psen1--TEMP--/genes)--FIX--, and [PSEN2[/genes/[psen2[/genes/[psen2[/genes/[psen2[/genes/[psen2--TEMP--/genes)--FIX--, with near-complete penetrance for many [PSEN1[/genes/[psen1[/genes/[psen1[/genes/[psen1[/genes/[psen1--TEMP--/genes)--FIX--
variants[7]. In [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, CAG-repeat expansion in
[HTT[/genes/[htt[/genes/[htt[/genes/[htt[/genes/[htt--TEMP--/genes)--FIX-- is the defining lesion, with repeat size strongly associated with onset and anticipation[8]. In ALS-FTD spectrum disease, the hexanucleotide repeat expansion in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- is the most common
inherited driver and can produce ALS, FTD, or mixed phenotypes in the same pedigree[9].
Late-onset neurodegenerative disease generally follows polygenic architecture. In Alzheimer's Disease, the [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX---[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- axis links lysosomal inefficiency to protein aggregation and propagation[18][19].
Bi-allelic variants in [PRKN[/genes/[prkn[/genes/[prkn[/genes/[prkn[/genes/[prkn--TEMP--/genes)--FIX-- and [PINK1[/genes/[pink1[/genes/[pink1[/genes/[pink1[/genes/[pink1--TEMP--/genes)--FIX-- define key forms of early-onset PD and clarified pathways in mitochondrial quality control and [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX--[20].
The ALS-FTD spectrum is genetically heterogeneous but converges on RNA biology, stress granule dynamics, and proteostasis. [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- repeat expansion remains the dominant inherited
cause in many populations[9]. [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- mutations are clinically actionable following
development of antisense therapy, marking a transition from gene discovery to precision treatment in neurodegeneration[21]. Mutations in [TARDBP[/genes/[tardbp[/genes/[tardbp[/genes/[tardbp[/genes/[tardbp--TEMP--/genes)--FIX-- and [FUS[/entities/[fus[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX-- further establish RNA-binding protein dysfunction as a central disease axis.
[HTT[/genes/[htt[/genes/[htt[/genes/[htt[/genes/[htt--TEMP--/genes)--FIX-- CAG expansion causes Huntington's Disease with repeat-length-dependent penetrance and age at onset[8]. Separately, [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- haplotypes and pathogenic variants contribute to primary tauopathies including Progressive Supranuclear Palsy and Corticobasal Degeneration, extending tau] genetics beyond Alzheimer pathology[22].
Cross-disease genetics shows that different diagnoses often converge on overlapping cellular systems: lysosome-autophagy, [microglial activation], synaptic maintenance, RNA metabolism, and mitochondrial homeostasis[3][4]. This convergence supports a portfolio strategy for drug development:
Recent advances in [genetics[/mechanisms/[genetics[/mechanisms/[genetics[/mechanisms/[genetics[/mechanisms/[genetics--TEMP--/mechanisms)--FIX-- show that [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- risk is shaped by ancestry-aware loci, [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX-- modifier effects, and blood-accessible molecular correlates that improve translational stratification.
The study of Genetics Of Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 31 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 49%